Applied NeuroSolutions

Applied NeuroSolutions was a biotechnology company focused on developing diagnostic and therapeutic products for Alzheimer's disease. The company's core technology centered on the Tau protein, specifically the detection and inhibition of phosphorylated tau (P-Tau), which is associated with the formation of neurofibrillary tangles in the brain. Their portfolio included a cerebrospinal fluid-based diagnostic test and a series of small molecule therapeutic candidates. A major milestone for the company was a multi-year collaboration with Eli Lilly to identify and develop compounds that could prevent or reverse Tau-related pathology. However, the company faced significant financial hurdles and ceased operations around 2012.